OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

Core Insights - OKYO Pharma Limited has been granted a key European Patent for "Compositions Comprising Chemerin Analogs and Methods of Use," which strengthens its intellectual property position in the ocular therapy market [1][2] - The patent relates to novel OK-101 chemerin analogs aimed at treating inflammatory dry eye disease (DED) and neuropathic corneal pain (NCP), addressing significant unmet medical needs [1][2] - OK-101 is a lipid-conjugated chemerin peptide agonist designed to enhance the treatment of DED and NCP, showing promising results in preclinical and Phase 2 clinical trials [3][4] Company Overview - OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for DED and NCP, with its shares traded on the NASDAQ Capital Market [4] - The company is advancing its pipeline candidates and exploring strategic partnerships to accelerate development and commercialization [2][4] - OK-101 has demonstrated anti-inflammatory and pain-reducing efficacy in mouse models and has recently completed a Phase 2 trial for DED, with plans for a Phase 2 trial for NCP [3][4]